Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development expenses	$ 3,687,999	$ 2,060,815	$ 7,865,249	$ 5,446,718
General and administrative expenses	3,274,325	1,846,214	7,252,371	5,428,098
Total operating expenses	6,962,324	3,907,029	15,117,620	10,874,816
Loss from operations	(6,962,324)	(3,907,029)	(15,117,620)	(10,874,816)
Other income:
Interest income	1,358	1,207	2,617	54,242
Loss before income taxes	(6,960,966)	(3,905,822)	(15,115,003)	(10,820,574)
Benefit from income taxes	0	0	4,516,488	0
Net loss	(6,960,966)	(3,905,822)	(10,598,515)	(10,820,574)
Comprehensive loss	$ (6,960,966)	$ (3,905,822)	$ (10,598,515)	$ (10,820,574)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.24)	$ (0.21)	$ (0.43)	$ (0.73)
Net loss per share, diluted (in dollars per share)	$ (0.24)	$ (0.21)	$ (0.43)	$ (0.73)
Weighted average common shares outstanding, basic (in shares)	28,425,850	18,961,619	24,639,299	14,892,764
Weighted average common shares outstanding, diluted (in shares)	28,425,850	18,961,619	24,639,299	14,892,764